Literature DB >> 7137982

Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations.

J C Rotschafer, K Crossley, D E Zaske, K Mead, R J Sawchuk, L D Solem.   

Abstract

Studies of the pharmacokinetics of vancomycin were conducted in a group of 28 patients with serious staphylococcal infection. Serum specimens were collected before and on 11 occasions after vancomycin administration. Serum concentration time data were fitted to a biexponential equation, using nonlinear regression analysis. A prolonged distribution phase with a half-life of 0.5 +/- 0.3 h (standard deviation) and a central component volume of 9.0 +/- 4.0 liters were demonstrated. Wide interpatient variation was observed in the terminal half-life which ranged from 3 to 13 h (mean, 6 h) and in the distribution volume which ranged from 14 to 111 liters (mean, 39 liters). A correlation of 0.45 (Pearson product moment correlation coefficient) was found between vancomycin clearance and creatinine clearance. Multiple regression analyses demonstrated that 50% of the variance (R2) in the terminal half-life and vancomycin clearance could be explained on the basis of renal function, volume of distribution, age, weight, and sex. These observations suggest that adults with normal renal function should receive an initial dosage of 6.5 to 8 mg of vancomycin per kg intravenously over 1 h every 6 to 12 h. After 24 h, and through the period of therapy, trough and peak serum vancomycin concentrations should be monitored, and the dose and dosage interval should be changed to produce the desired peak (30 to 40 micrograms/ml) and trough (5 to 10 micrograms/ml) levels.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7137982      PMCID: PMC183754          DOI: 10.1128/AAC.22.3.391

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

Review 1.  Clinical pharmacokinetics (second of two parts).

Authors:  D J Greenblatt; J Koch-Weser
Journal:  N Engl J Med       Date:  1975-11-06       Impact factor: 91.245

2.  Some laboratory and clinical experiences with a new antibiotic, vancomycin.

Authors:  J E GERACI; F R HEILMAN; D R NICHOLS; G T ROSS; W E WELLMAN
Journal:  Proc Staff Meet Mayo Clin       Date:  1956-10-17

3.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

4.  Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment.

Authors:  S Riegelman; J C Loo; M Rowland
Journal:  J Pharm Sci       Date:  1968-01       Impact factor: 3.534

5.  Vancomycin. A second look.

Authors:  A L Esposito; R A Gleckman
Journal:  JAMA       Date:  1977-10-17       Impact factor: 56.272

6.  Comparison of a radioimmunoassay and a microbiological assay for measurement of serum vancomycin concentrations.

Authors:  K B Crossley; J C Rotschafer; M M Chern; K E Mead; D E Zaske
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

7.  An outbreak of infections caused by strains of Staphylococcus aureus resistant to methicillin and aminoglycosides. I. Clinical studies.

Authors:  K Crossley; D Loesch; B Landesman; K Mead; M Chern; R Strate
Journal:  J Infect Dis       Date:  1979-03       Impact factor: 5.226

Review 8.  Vancomycin revisited.

Authors:  F V Cook; W E Farrar
Journal:  Ann Intern Med       Date:  1978-06       Impact factor: 25.391

9.  Vancomycin therapy in patients with impaired renal function: a nomogram for dosage.

Authors:  R C Moellering; D J Krogstad; D J Greenblatt
Journal:  Ann Intern Med       Date:  1981-03       Impact factor: 25.391

View more
  45 in total

1.  Pulmonary disposition of vancomycin in critically ill patients.

Authors:  H Georges; O Leroy; S Alfandari; B Guery; M Roussel-Delvallez; C Dhennain; G Beaucaire
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-05       Impact factor: 3.267

2.  Prediction of serum vancomycin concentrations following intraperitoneal loading doses in continuous ambulatory peritoneal dialysis patients with peritonitis.

Authors:  G R Bailie; G Eisele; R A Venezia; D Yocum; A Hollister
Journal:  Clin Pharmacokinet       Date:  1992-04       Impact factor: 6.447

3.  Protein binding of vancomycin in a patient with immunoglobulin A myeloma.

Authors:  T G Cantú; J D Dick; D E Elliott; R L Humphrey; D M Kornhauser
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

4.  Increased vancomycin dosing requirements in sickle cell disease due to hyperfiltration-dependent and independent pathways.

Authors:  Jin Han; Xu Zhang; Jennifer Oderinde; Santosh L Saraf; Michel Gowhari; Joharah Hassan; Shivi Jain; Victor R Gordeuk; Robert E Molokie
Journal:  Haematologica       Date:  2017-05-04       Impact factor: 9.941

5.  Clearance from dialysate and equilibration of intraperitoneal vancomycin in continuous ambulatory peritoneal dialysis.

Authors:  D Neal; G R Bailie
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

6.  Effects of SCH27899 (Ziracin), an oligosaccharide everninomicin antibiotic, on urate kinetics in humans.

Authors:  Satoru Nagashima; Masayuki Niwa; Katsuyuki Nishiki; Tatsuo Hosoya; Akira Hishida; Toshihiko Uematsu
Journal:  Eur J Clin Pharmacol       Date:  2004-04-16       Impact factor: 2.953

Review 7.  Pharmacokinetic optimisation of vancomycin therapy.

Authors:  W G Leader; M H Chandler; M Castiglia
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics of vancomycin.

Authors:  G R Matzke; G G Zhanel; D R Guay
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

9.  Concentrations of vancomycin in bone and serum of normal rabbits and those with osteomyelitis.

Authors:  K J Wilson; J T Mader
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

Review 10.  Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients.

Authors:  Benoit Blanchet; Vincent Jullien; Christophe Vinsonneau; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.